Understanding how piperacillin/tazobactam works in pregnant women and their newborns

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize the population pharmacokinetics of piperacillin/tazobactam administered intravenously to pregnant women during pregnancy and delivery. It will evaluate the pharmacodynamic effectiveness and safety of this antibiotic in mothers whose newborns are at high risk for early-onset neonatal sepsis. By analyzing how the drug behaves in both maternal and neonatal populations, the study seeks to optimize treatment protocols for this vulnerable group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients over 18 years old;
* Pregnant women whose baby are at high risk of developing early-onset sepsis after birth have indications to use preventive or therapeutic antibiotics, and the antibiotics used are PIP/TAZO；
* Patients and their families are fully aware of the research content and sign the informed consent form.

Exclusion Criteria:

* Intolerance or serious adverse reactions to antibiotic use;
* Patients who stopped using PIP/TAZO more than 24 hours before delivery;
* Receiving other systemic trial drugs;
* There are other factors that the researchers think are not suitable for inclusion

Where it's running

• Shandong Provincial Hospital
  Jinan, China Recruiting

Study contacts

• Principal investigator: Wei Zhao, Ph.D — Shandong University
• Study coordinator: Wei Zhao, Ph.D
• Email: zhao4wei2@hotmail.com
• Phone: 86053188383308

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Selective antibiotics when symptoms develop versus universal antibiotics for preterm neonates

  In preterm babies at risk for sepsis, researchers test whether giving antibiotics only to those who show symptoms is as safe as giving antibiotics to all at-risk babies in the first week of life.

  Recruiting at 9 sites Phase 3 Indian Council of Medical Research · Chandigarh, Chandigarh and 8 other locations · NCT06377397

• Using presepsin to reduce unnecessary antibiotics in preterm infants

  This study is testing if using a blood marker called presepsin can help reduce unnecessary antibiotic use in preterm infants at risk for infection.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT06100614

• Amniotic fluid and the extremely preterm baby's gut

  We will see if amniotic fluid from extremely preterm births (24+0 to 27+6 weeks) shows changes that relate to gut problems such as necrotizing enterocolitis or sepsis in very preterm infants.

  Recruiting at 2 sites Maxima Medical Center · Amsterdam and 1 other locations · NCT07152106

• POP-Score: A simple, non-invasive test to see if newborns might have early infection

  This study tests whether the POP-Score, a non-invasive measure using NIRS and routine vitals, can predict elevated CRP in term and near-term neonates within 48 hours of birth.

  Recruiting Medical University of Graz · Graz, Styria · NCT07109856

• MDW as a new marker for late-onset sepsis in preterm newborns

  Researchers are testing whether monocyte distribution width (MDW) can help detect late-onset neonatal sepsis in preterm babies.

  Recruiting Tanta University · Tanta · NCT07821190

• Comparing Dopamine and Norepinephrine for Low Blood Pressure in Very Preterm Infants with Sepsis

  This study is testing whether Dopamine or Norepinephrine works better to help very preterm infants with low blood pressure caused by sepsis.

  Recruiting at 20 sites Mount Sinai Hospital, Canada · Phoenix, Arizona and 21 other locations · NCT05347238

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.